PTC Therapeutics (NASDAQ:PTCT) CFO Pierre Gravier Sells 2,992 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Pierre Gravier sold 2,992 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $207,525.12. Following the completion of the transaction, the chief financial officer owned 87,318 shares in the company, valued at $6,056,376.48. This trade represents a 3.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Pierre Gravier also recently made the following trade(s):

• On Tuesday, January 6th, Pierre Gravier sold 2,139 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $164,596.05.

PTC Therapeutics Stock Up 1.1%

PTCT traded up $0.76 during trading on Friday, reaching $70.66. 2,532,077 shares of the stock traded hands, compared to its average volume of 1,290,685. The stock’s 50-day moving average is $75.01 and its 200 day moving average is $67.78. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The stock has a market capitalization of $5.67 billion, a PE ratio of 8.25 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business had revenue of $164.68 million during the quarter, compared to the consensus estimate of $281.45 million. During the same period last year, the business posted ($0.85) earnings per share. The business’s revenue was down 22.7% on a year-over-year basis. As a group, equities research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PTCT. Ameritas Investment Partners Inc. increased its stake in PTC Therapeutics by 3.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 231 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares during the last quarter. Allworth Financial LP lifted its holdings in PTC Therapeutics by 63.8% during the fourth quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 247 shares during the period. Optiver Holding B.V. boosted its position in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC grew its stake in PTC Therapeutics by 5.6% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 4,963 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 265 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Wells Fargo & Company reduced their target price on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a research note on Friday. Jefferies Financial Group upped their price target on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. The Goldman Sachs Group increased their price target on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.73.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company reported full‑year 2025 product and royalty revenue that exceeded guidance, strong early commercial uptake of Sephience™ (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M), and $1.95B cash on hand — supports runway for commercialization and R&D. Read More.
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but kept a “buy” rating, signaling continued analyst conviction and providing potential support for the stock. Read More.
• Neutral Sentiment: Full Q4 earnings call transcript and highlights are available for investors parsing management commentary for drivers of the revenue miss (useful to judge one‑time items vs. sustained weakness). Read More.
• Negative Sentiment: Q4 results missed badly: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — revenue fell ~22.7% YoY. That miss is the primary near‑term driver of investor concern. Read More.
• Negative Sentiment: Management set FY‑2026 revenue guidance of $700M–$800M versus street consensus near $974M — a sizable downward gap that reduces near‑term upside and likely drove negative sentiment. Read More.
• Negative Sentiment: Regulatory uncertainty after PTC withdrew a Translarna NDA has prompted new questions about that program’s prospects and potential revenue contribution. Read More.
• Negative Sentiment: Insider selling: VP Mark Elliott Boulding sold ~5,894 shares across Feb. 17–18 (recent Form 4 filings), a modest but visible reduction that some investors view negatively. Read More.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.